Oyster raises $60m to advance brain-targeted protein degraders
A promising drug mechanism still needs to reach the part of the body where it is needed.

A promising drug mechanism still needs to reach the part of the body where it is needed.
What happened
Oyster Therapeutics, formerly Kesmalea, announced a $60m Series A-2 led by 4BIO Capital, with participants including Eli Lilly. Funding supports development of an oral, brain-penetrant drug designed to remove disease-associated tau protein, alongside its protein-degradation platform.
Why it matters
Reaching the brain is a major challenge in drug development. Oyster is targeting that problem in diseases associated with abnormal tau, including Alzheimer's.
The bigger picture
The financing supports development towards clinical testing. Evidence from that programme will determine whether the approach can become a useful treatment.
